Register for the 8th Neuroimmunology Drug Development Summit
Please select the appropriate price when booking. Bookings are subject to approval.
All prices are shown in US $.
Register by Friday, January 16 & Save up to $900
Drug Developer Pricing*
Conference + Workshop Day
(Save $900)
$3,297
On the Door: $4,197
Conference Only
(Save $500)
$2,499
On the Door: $2,999
Academic Pricing**
Conference + Workshop Day
(Save $900)
$2,697
On the Door: $3,597
Conference Only
(Save $500)
$2,099
On the Door: $2,599
Service Provider Pricing***
Conference + Workshop Day
(Save $900)
$4,197
On the Door: $5,097
Conference Only
(Save $500)
$3,199
On the Door: $3,699
* To be eligible for this price, the group or individuals must be from a biotech or pharma company that has a publicly available pipeline, and does not offer pay for services.
** To be eligible for this price, the group or individual must be full-time academic(s).
*** If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Inquire to learn more.
Unlock Group Discounts
Bring your team to maximize ROI and secure group discounts.
10 % Off
When registering 2 attendees from one company
15% Off
When registering 3 attendees from one company
20% Off
When registering 4+ attendees from one company
Need Assistance?
If you have any questions about registration pricing, discounts or would like help in the booking process, contact us and one of the team will get back to you.
Explore the Full Event Guide
- 80+ discovery, preclinical & translational neuroimmunology experts from leading biopharma and academia
- 3 days of cutting-edge insights across neuroinflammatory targets, glial biology, biomarkers & translational innovation
- Deep-dive agenda strand: Bridging Peripheral & Central Immunity, exploring next-generation B & T cell targets enabling earlier, more precise CNS intervention
- Hear from 25+ top speakers from Sanofi, Biogen, Merck, AbbVie, BMS, Lundbeck, Vigil Neuroscience and more
- Unmissable debates on humanized models, emerging insights into inflammation-driven psychosis mechanisms, and early clinical signals from novel neuroimmune-targeting therapies
